Philip Morris International Inc
- Industry
- Tobacco
- Exchange
- US
- Country
- USA
- IPO date
- Mar 17, 2008
- Employees
- 84,900
- Website
- www.pmi.com
Composite valuation range · conservative $90–$110 / fair $125–$150 / optimistic $165–$185. At $195.66, Above the optimistic ceiling · future growth overdrawn.
At publication $188.99 (May 25, 2026)
Data from EODHD, shown in the reporting currency; for reference only, not investment advice.
Philip Morris International Inc. operates as a tobacco company. The company offers cigarettes and smoke-free products, including heat-not-burn, e-vapor, and oral nicotine products under the IQOS, VEEV, and ZYN brands; and consumer accessories, such as lighters and matches. It also offers wellness products. The company was incorporated in 1987 and is headquartered in Stamford, Connecticut.
History
Philip Morris International Inc. was incorporated in 1987 and is headquartered in Stamford, Connecticut, with its shares first listed on March 17, 2008. The company has built a multi-brand cigarette portfolio including Marlboro, Parliament, Chesterfield, L&M and Philip Morris, while since 2008 investing over $16 billion in smoke-free products. Its smoke-free lineup now spans the IQOS heat-not-burn platform, ZYN oral nicotine pouches and the VEEV e-vapor brand, with ZYN added through the Swedish Match acquisition. As of 2025 it employed about 84,900 people.
Industry position
Philip Morris International operates as a global tobacco and nicotine company, selling cigarettes in roughly 170 markets and smoke-free products in 106 markets, with Japan its largest market at $4.2 billion of net revenue in 2025. Marlboro accounted for about 43% of 2025 cigarette shipment volume, and its top five international brands made up 81%. In 2025 net revenue reached $40.648 billion, of which smoke-free products contributed $16.854 billion, or 41.5%, rising to 43% by the first quarter of 2026 with over 43 million estimated adult users. The company estimates IQOS holds about 76% of global heated-tobacco volume, while ZYN held roughly two-thirds of the U.S. oral nicotine pouch value share in 2025; its main competitors include BAT, Japan Tobacco, Imperial Brands and Altria.